A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Single Dose of Intravenous CS 1103 Following a Single Intravenous Dose of Fentanyl in Healthy Subjects With Naloxone Blockade
Clear Scientific, Inc.
16 participants
May 1, 2026
INTERVENTIONAL
Conditions
Summary
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CS-1103 (1,000 mg), given by intravenous (IV) infusion in healthy participants in the presence of a clinically relevant dose of fentanyl (200 μg, IV), with naloxone blockade (400 μg, IV).
Eligibility
Inclusion Criteria4
- Healthy participants aged 18 to 55 years, inclusive;
- Have prior experience with opioids, such as from a dental procedure, chronic pain management, or previous inpatient surgical procedure;
- A body mass index between 18.0 to 30.0 kg/m2, inclusive, and a minimum body weight of 56 kg;
- Females must not be lactating and must have a negative pregnancy test during screening and admission.
Exclusion Criteria3
- Estimated glomerular filtration rate <90 mL/min/1.73 m2;
- History of cardiovascular disease;
- History of any clinically important disease or disorder which, in the opinion of the Investigator, may interfere with safe study participation.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Naloxone for intravenous administration
Fentanyl for intravenous administration
Sterile Saline for intravenous administration
CS-1103 for intravenous administration
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07459166